The Phase III study will evaluate the efficacy of Lymphoseek to identify lymph nodes that may be predictive of determining whether a patient’s cancer has spread into the lymphatic system.
David Bupp, president and CEO of Neoprobe, said: “Neoprobe is pleased to announce the initiation of its first Phase III study (NEO3-05) for Lymphoseek. At the present time, we have multiple sites initiated and by the end of this month, we expect to have more sites enrolling patients in the study than participated in the very successful Phase II clinical study of Lymphoseek.
“During July and August, additional sites will be initiated to commence patient enrollment including international sites, which will bring the total number of sites participating in the trial to approximately 20.”